By Gnaneshwar Rajan and Maggie Fick (Reuters) -U.S.-based vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in the Czech Republic to Wegovy maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.

With the purchase of a plant in the Czech Republic, Novo Nordisk is saying “jak se máš” to hundreds of new employees—and expanding its production footprint along the way. | Novavax is selling its 150,

COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.

Novavax plans to sell its Czech Republic manufacturing site to a pharmaceutical giant. The deal stands to drive $200 million to the Gaithersburg vaccine maker.

Novavax Inc. shares climbed over 4% pre-market Wednesday following the announcement of a $200 million deal to sell its Bohumil, Czech Republic manufacturing facility to Novo Nordisk. The definitive agreement includes the transfer of a 150,